EXC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Exelon is not a strong buy right now for a beginner long-term investor, but it is also not a sell. At a pre-market price of 44.28, the stock is trading near short-term support while fundamentals and Q1 results are solid, yet the near-term setup is weighed down by weak technical momentum and a wave of negative analyst revisions tied to regulatory overhang. For an impatient investor, the best direct call is to hold and wait rather than buy immediately.
EXC is technically weak in the near term. The MACD histogram is negative and still expanding lower, which signals downward momentum. RSI_6 at 20.0 is very oversold, but it is not yet providing a clear reversal signal. Moving averages are converging, suggesting a possible base-building phase rather than a clean uptrend. Price at 44.28 is just below the pivot at 46.02 and slightly below first support at 44.67, with next support at 43.84. That means the stock is sitting in a fragile area: it could stabilize, but it is not showing a confirmed upside breakout.
["Q1 2026 adjusted operating earnings beat expectations at $0.91 per share.", "Q1 2026 revenue rose 7.86% year over year to $7.242 billion.", "Management reaffirmed 2026 adjusted operating earnings guidance of $2.81 to $2.91 per share.", "Company plans nearly $10 billion of investment in 2026, supporting regulated growth visibility.", "ComEd received an energy efficiency award, adding a small positive ESG/customer-service headline.", "Hedge funds are buying, with a large reported increase in buying activity over the last quarter."]
["Recent analyst revisions are mostly negative, with multiple target cuts across Morgan Stanley, KeyBanc, RBC, Jefferies, Mizuho, Barclays, and BMO.", "Regulatory overhang in Pennsylvania and Maryland remains the main concern and is limiting multiple expansion.", "PECO withdrew its rate case, which removed a near-term catalyst and reinforced the regulatory pressure narrative.", "Technical momentum is weak, with a negative MACD histogram and the price sitting near support rather than in a confirmed uptrend.", "Options flow today leans bearish on volume, with put volume materially above call volume.", "Gross margin slipped slightly year over year in the latest quarter."]
In Q1 2026, Exelon delivered a good quarter for a regulated utility. Revenue increased 7.86% year over year to $7.242 billion, net income rose to $919 million, and EPS came in at $0.90-$0.91, ahead of expectations. The company also confirmed full-year 2026 guidance and maintained its quarterly dividend at $0.42. Growth is steady rather than exciting, but the latest quarter shows healthy earnings execution and modest top-line expansion.
Analyst sentiment has turned cautious recently. The trend shows multiple target cuts and several downgrades from Buy/Overweight to Hold/Neutral/Market Perform, largely because of regulatory uncertainty and the PECO rate case withdrawal. Price targets now cluster around $43 to $55, with several firms near $48-$50. The wall street pros view is mixed: bulls like the regulated utility profile, dividend, and infrastructure spend, but bears see limited upside, entrenched regulatory risk, and weak catalyst visibility. Overall, the analyst tone is neutral-to-negative in the short term.
